FTC signals scrutiny of Novo’s bid for Metsera

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Novo Nordisk’s offer to buy obesity drug developer Metsera may run afoul of federal law on premarket review of company acquisitions, the Federal Trade Commission told the companies in a Tuesday letter. While the FTC said its staff and commissioners “take no position” on the deal’s legality, the letter indicated that the structure of Novo’s propos ...